Poster: ABCL-320 Initial Safety Run-In Results of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL
Clinical Lymphoma Myeloma and Leukemia（2022）
摘要
ADC Therapeutics SA; medical writing: CiTRUS Health Group.
更多查看译文
关键词
ABCL,antibody-drug conjugate,CD19,loncastuximab tesirine,relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL),Phase III
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要